| HOME >> BIOLOGY >> TECHNOLOGY |
Net loss for the three- and nine-month period ended December 31, 2007 was $900,000 or $0.06 per diluted share, and $3.1 million, or $0.23 per diluted share, respectively. Net loss for the corresponding periods in the prior year was $563,000, or $0.07 per diluted share, and $4.0 million, or $0.51 per diluted share, respectively.
Mr. Kaysen continued, "Based on our year-to-date performance, we are pleased to raise our fiscal year 2008 revenue guidance to approximately $13.5 million. In addition, we continue to believe we can grow fiscal 2009 sales 30% to 40% and sales to customers in the U.S. over 60% based on the continued market adoption of Urgent PC system and the continued successful expansion of our U.S. direct sales force."
As previously announced, Uroplasty will host an audio conference call
on Monday, February 11, 2008, at 10.00 am central time to review the
financial results for the third fiscal quarter. David Kaysen, President and
Chief Executive Officer and Medi Jiwani, Vice President, Chief Financial
Officer and Treasurer will host the call. Individuals wishing to
participate in the conference call should dial 800-240-5318 (domestic) or
303-262-2140 (international). An audio replay will be available two hours
after the call for 30 days by dialing (800) 405-2236 (domestic) or
303-590-3000 (international), with the passcode 11108161#.
UROPLASTY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Nine Months Ended
December 31, December 31,
2007 2006 2007 2006
Net sales $3,729,314 $2,158,273 $9,717,531 $5,683,253
Cost
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2008 PR Newswire. All rights reserved |